BioCentury
ARTICLE | Finance

Ebb & Flow

August 25, 2008 7:00 AM UTC

Genentech (NYSE:DNA) disclosed in an SEC filing last week details of the retention and severance plans it has put in place to cover “substantially all” of its employees and executives as the biotech negotiates over the proposed takeover by Roche.

The retention plan provides incentives to stay through June 30, 2009, and in some cases through June 30, 2010, following a merger...